



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

May 6, 2020

Michael W. Nall  
President and Chief Executive Officer  
Biocept, Inc.  
5810 Nancy Ridge Drive  
San Diego, CA 92121

**Re: Biocept, Inc.**  
**Preliminary Proxy Statement on Schedule 14A**  
**Filed April 20, 2020**  
**File No. 001-36284**

Dear Mr. Nall:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Charles Bair